ArticleDiabetes, obesity & metabolism2026
Comparison of Diluted Insulin (U10) Versus Standard (U100) Insulin in Automated Insulin Delivery Systems: Reducing Time Below Range in Young Children.
Article in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comparison of Diluted Insulin (U10) Versus Standard (U100) Insulin in Automated Insulin Delivery Systems: Reducing Time Below Range in Young Children.Diabetes, obesity & metabolism · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundTreating young children with Type 1 diabetes (CwT1D) is challenging due to their very small need for insulin. We investigated the safety of diluted insulin (U10) in the AID system and how its use affected glycaemic outcomes compared to standard insulin.
methodsPatients aged 0-4 years who initiated treatment with diluted insulin in an AID system during the years 2020-2025 were identified from the diabetes registry (N = 19). They had a maximum daily insulin dose of ≤ 6 units. An age and gender-matched control group (N = 27) using standard insulin (U100) in an AID system was determined. Longitudinal CGM outcomes were analysed within the treatment group from the start of diluted insulin and between groups from diagnosis over 12 months to assess time-by-treatment effects.
resultsAfter 3 months of diluted insulin use, TBR < 3.9 and TBR < 3.0 decreased significantly (from 4.6% ± 4.1% to 2.7% ± 2.5%, p = 0.008; from 1.2% ± 1.8% to 0.4% ± 0.6%, p = 0.01, respectively) and remained low through 12 months. Compared with controls, children using diluted insulin had lower TBR < 3.9 mmol/L at later follow-up visits. In the HbA1c-adjusted mixed-effects model, the between-group difference in change from 3 months was -1.85 percentage points at 9 months (95% CI: -3.26 to -0.44, p = 0.010) and -1.52 percentage points at 12 months (95% CI: -2.92 to -0.13, p = 0.032). No significant between-group changes in other CGM measures over time were observed.
conclusionThe use of diluted insulin in young CwT1D, who require low insulin doses and use an automated insulin delivery system, reduces time below range with no evidence of increased hyperglycaemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.